This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset

Core Insights - DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals, valued at approximately $3.89 million, as reported in an SEC filing dated February 17, 2026 [1][2] - The value of Syndax's stake at the end of the fourth quarter decreased by $1.87 million due to share sales and price movements [2] Company Overview - Syndax Pharmaceuticals is a biotechnology company focused on developing novel cancer therapies, particularly for hematologic malignancies and immune-mediated conditions [5] - The company has a market capitalization of $2.1 billion and reported revenue of $172.4 million for the trailing twelve months (TTM) [4] - Syndax's net income for the TTM is reported at a loss of $285.4 million [4] Financial Performance - As of the latest report, Syndax shares are priced at $24.23, reflecting a 72% increase over the past year, significantly outperforming the S&P 500, which rose about 15% in the same period [7] - The fund's position in Syndax now represents 1.36% of its $430.52 million reportable assets, down from 1.90% in the previous quarter [7] Product Pipeline and Market Position - Syndax is advancing its pipeline with products like SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease, alongside other therapies [8] - The company is transitioning from a clinical-stage to a commercial-stage biotech, generating real revenue and showing strong momentum from two commercial products [9] - This transition is significant but comes with increased operating costs and substantial ongoing losses [9] Strategic Insights - The recent share sale by DAFNA Capital Management indicates a disciplined approach to managing exposure within a biotech-heavy portfolio, especially after a significant stock price increase [6] - Syndax's ability to build a credible commercial base while advancing its pipeline positions it as a key innovator in the biopharmaceutical sector, though it may also lead to volatility as market expectations adjust [10]